Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.
Animals
Arginine
/ deficiency
Argininosuccinate Synthase
/ deficiency
Breast Neoplasms
/ genetics
CRISPR-Cas Systems
Cell Line, Tumor
Chemokine CCL2
/ genetics
Drug Resistance, Neoplasm
/ genetics
Female
Gene Knockout Techniques
Humans
Hydrolases
/ pharmacology
Inflammation
/ genetics
Male
Mice
Mice, Inbred BALB C
Mice, Nude
Models, Biological
Molecular Targeted Therapy
Polyethylene Glycols
/ pharmacology
Precision Medicine
Prostatic Neoplasms
/ genetics
Signal Transduction
Triggering Receptor Expressed on Myeloid Cells-1
/ antagonists & inhibitors
Up-Regulation
Xenograft Model Antitumor Assays
ADI resistance
CCL2
CRISPR/Cas9
TREM1
arginine starvation
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
08
2020
accepted:
01
01
2021
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
30
7
2021
Statut:
epublish
Résumé
Arginine synthesis deficiency due to the suppressed expression of ASS1 (argininosuccinate synthetase 1) represents one of the most frequently occurring metabolic defects of tumor cells. Arginine-deprivation therapy has gained increasing attention in recent years. One challenge of ADI-PEG20 (pegylated ADI) therapy is the development of drug resistance caused by restoration of ASS1 expression and other factors. The goal of this work is to identify novel factors conferring therapy resistance.
Identifiants
pubmed: 33664852
doi: 10.7150/thno.51795
pii: thnov11p3624
pmc: PMC7914361
doi:
Substances chimiques
CCL2 protein, human
0
Chemokine CCL2
0
TREM1 protein, human
0
Triggering Receptor Expressed on Myeloid Cells-1
0
Polyethylene Glycols
3WJQ0SDW1A
Arginine
94ZLA3W45F
Hydrolases
EC 3.-
ADI PEG20
EC 3.5.3.6
Argininosuccinate Synthase
EC 6.3.4.5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3624-3641Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
JAMA Oncol. 2017 Jan 1;3(1):58-66
pubmed: 27584578
J Biol Chem. 2012 Oct 19;287(43):36593-608
pubmed: 22927430
Sci Adv. 2017 May 19;3(5):e1603204
pubmed: 28560349
Diagn Pathol. 2014 Nov 29;9:221
pubmed: 25432701
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Clin Cancer Res. 2019 Aug 15;25(16):5107-5121
pubmed: 31164374
Cancer Chemother Pharmacol. 2018 Sep;82(3):429-440
pubmed: 29971467
Ann Oncol. 2018 Jun 1;29(6):1402-1408
pubmed: 29659672
Front Immunol. 2015 Aug 18;6:422
pubmed: 26347745
Mol Cancer Ther. 2016 Sep;15(9):2198-208
pubmed: 27256378
BMC Cancer. 2014 Sep 20;14:686
pubmed: 25240403
Cancer Sci. 2020 Jan;111(1):47-58
pubmed: 31710162
J Carcinog. 2005 Apr 20;4(1):7
pubmed: 15842733
Oncogene. 2016 Mar 31;35(13):1632-42
pubmed: 26096933
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
PLoS One. 2015 Feb 02;10(2):e0115116
pubmed: 25642940
Clin Cancer Res. 2019 Aug 15;25(16):5122-5134
pubmed: 31113844
Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14147-52
pubmed: 25122679
Br J Cancer. 2010 Sep 28;103(7):954-60
pubmed: 20808309
Sci Signal. 2014 Apr 01;7(319):ra31
pubmed: 24692592
Oncotarget. 2016 Aug 9;7(32):51525-51534
pubmed: 27409666
Clin Cancer Res. 2017 Oct 15;23(20):6094-6100
pubmed: 28754816
J Clin Invest. 2007 Oct;117(10):3097-106
pubmed: 17853946
Immunol Lett. 2008 Mar 15;116(2):111-6
pubmed: 18192027
Oncotarget. 2016 May 10;7(19):28697-710
pubmed: 26885690
Genome Biol. 2014;15(12):550
pubmed: 25516281
Curr Opin Immunol. 2016 Feb;38:59-66
pubmed: 26682763
Pharmacol Ther. 2017 Sep;177:81-95
pubmed: 28245991
Transl Oncol. 2020 Feb;13(2):355-364
pubmed: 31887630
Clin Cancer Res. 2013 Jun 1;19(11):2861-72
pubmed: 23549872
Nucleic Acids Res. 2013 May 1;41(10):e108
pubmed: 23558742
J Immunol. 2015 Feb 15;194(4):1417-21
pubmed: 25595774
Clin Cancer Res. 2017 Jan 1;23(1):137-148
pubmed: 27354473
Biomed Pharmacother. 2019 Oct;118:109210
pubmed: 31330440
Nature. 2015 Nov 19;527(7578):379-383
pubmed: 26560030
Cell Death Dis. 2014 Sep 04;5:e1409
pubmed: 25188519
J Intern Med. 2014 Nov;276(5):425-43
pubmed: 24935761
Oncotarget. 2017 Oct 27;8(57):96468-96469
pubmed: 29228540
Ann Surg Oncol. 2015 Sep;22(9):3121-9
pubmed: 25465376
Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt A):1717-1727
pubmed: 29477409
Mol Med. 2014 Mar 24;20:138-46
pubmed: 24531836
Cancer Sci. 2019 Jan;110(1):279-288
pubmed: 30426599
Cancer Res. 2009 Jan 15;69(2):700-8
pubmed: 19147587
Mol Oncol. 2014 Oct;8(7):1231-9
pubmed: 24816187
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Cell Death Dis. 2012 Jul 05;3:e342
pubmed: 22764101
Cytokine Growth Factor Rev. 2010 Feb;21(1):41-8
pubmed: 20005149
J Immunol. 2009 Aug 1;183(3):2027-36
pubmed: 19596984
Cell Rep. 2016 Aug 9;16(6):1604-1613
pubmed: 27452468
Oncol Lett. 2018 Jul;16(1):1267-1274
pubmed: 30061946
Cancer Res. 2016 Sep 1;76(17):5006-18
pubmed: 27364555
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Theranostics. 2020 Jan 1;10(2):829-840
pubmed: 31903153
Br J Cancer. 2018 Mar 6;118(5):670-678
pubmed: 29381686
Oncotarget. 2015 Mar 20;6(8):6295-309
pubmed: 25749046
Cell Physiol Biochem. 2018;51(2):854-870
pubmed: 30466103
Mol Cancer Ther. 2013 Nov;12(11):2581-90
pubmed: 23979920
Blood. 2011 Jul 28;118(4):936-45
pubmed: 21659545
J Clin Oncol. 2017 Jun 1;35(16):1778-1785
pubmed: 28388291
Oncotarget. 2016 Jan 26;7(4):4428-41
pubmed: 26684239
Clin Cancer Res. 2019 May 1;25(9):2708-2716
pubmed: 30796035
JCI Insight. 2020 Mar 12;5(5):
pubmed: 32027618
Mol Cancer Res. 2019 Feb;17(2):604-617
pubmed: 30446625
Oncoimmunology. 2018 Dec 13;8(3):1554967
pubmed: 30723587
Commun Biol. 2018 Oct 26;1:178
pubmed: 30393775
Cell Rep. 2017 Jan 24;18(4):991-1004
pubmed: 28122247